DS-8201a治疗HER2表达实体肿瘤的研究进展
Research Progress of DS-8201a in the Treat-ment of HER2-Expressing Solid Tumors
DOI: 10.12677/ACM.2023.1351063, PDF,   
作者: 王 宁：大连医科大学研究生院，辽宁 大连；岳 麓*：青岛市市立医院肿瘤精准治疗中心，山东 青岛
关键词: DS-8201a；HER2；乳腺癌；胃癌；DS-8201a； HER2； Breast Cancer； Gastric Cancer
摘要: 在精准治疗背景下，针对各种肿瘤驱动基因的靶向治疗极大地改变了当今的治疗现状。表皮生长因子受体2 (Human Epidermal Growth Factor Receptor 2; HER2)是多种肿瘤的驱动基因，DS-8201a (Trastuzumab deruxtecan; T-Dxd)作为一种新型靶向HER2的抗体偶联药物(Antibody-Drug Conju-gates; ADC)，不仅对HER2过表达的肿瘤具有抗肿瘤作用，而且对于HER2低表达、扩增及突变患者也具有不错的疗效。目前DS-8201a已经在多种实体瘤中进行了广泛的临床研究。本文概述了DS-8201a的结构和作用特点，并介绍其在各种实体肿瘤中的研究进展，为未来的精准靶向治疗提供方向。
Abstract: In the context of precision therapy, targeted therapy for various tumor driver genes has greatly changed the current therapeutic status. The epidermal growth factor receptor 2 (HER2) is a wide variety of tumor driver gene, DS-8201a (Trastuzumab deruxtecan; T-Dxd; Enhertu) as a novel HER2-targeting Antibody-drug conjugates (ADC), not only has antitumor effect on tumors with overexpression of HER2, but also has efficacy in patients with low expression, amplification and mutation of HER2. DS-8201a has been extensively tested in clinical trials in a variety of solid tumors. This article summarizes the structure and functional characteristics of DS-8201a, and introduces its research progress in various solid tumors, and provides directions for future precise targeted therapy.
文章引用：王宁, 岳麓. DS-8201a治疗HER2表达实体肿瘤的研究进展[J]. 临床医学进展, 2023, 13(5): 7611-7618. https://doi.org/10.12677/ACM.2023.1351063

参考文献

[1] Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. [Google Scholar] [CrossRef] [PubMed]
[2] Kovtun, Y.V. and Goldmacher, V.S. (2007) Cell Killing by Anti-body-Drug Conjugates. Cancer Letters, 255, 232-240. [Google Scholar] [CrossRef] [PubMed]
[3] 曾铖, 张剑. 抗体偶联药物应用于乳腺癌治疗的研究进展[J]. 中国临床新医学, 2022, 15(6): 477-481.
[4] 陆宁, 佟仲生. 抗体药物偶联物在乳腺癌中的研究进展[J]. 中国慢性病预防与控制, 2021, 29(7): 535-538.
[5] Källsten, M., Hartmann, R., Kovac, L., et al. (2020) Investigating the Im-pact of Sample Preparation on Mass Spectrometry-Based Drug-to-Antibody Ratio Determination for Cysteine- and Ly-sine-Linked Antibody-Drug Conjugates. Antibodies (Basel), 93, Article No. 46. [Google Scholar] [CrossRef] [PubMed]
[6] 朱逸晖, 李婷, 胡夕春. Trastuzumab Deruxtecan的临床研究进展及展望——HER2耐药患者的新希望[J]. 中国癌症杂志, 2021, 31(8): 754-761.
[7] Doi, T., Shitara, K., Naito, Y., et al. (2017) Safety, Pharmacokinetics, and Antitumour Activity of Trastuzumab Deruxtecan (DS-8201), a HER2-Targeting Antibody-Drug Conjugate, in Patients with Advanced Breast and Gastric or Gastro-Oesophageal Tumours: A Phase 1 Dose-Escalation Study. The Lancet Oncology, 18, 1512-1522. [Google Scholar] [CrossRef] 
[8] Ogitani, Y., Aida, T., Hagihara, K., et al. (2016) DS-8201a, a Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Effi-cacy with Differentiation from T-DM1. Clinical Cancer Research, 22, 5097-5108. [Google Scholar] [CrossRef] 
[9] (2021) Trastuzumab Deruxtecan Data Impresses at ESMO. Cancer Discovery, 11, 2664-2665. [Google Scholar] [CrossRef] 
[10] Gonzalez-Angulo, A.M., Litton, J.K., Broglio, K.R., et al. (2009) High Risk of Recurrence for Patients with Breast Cancer Who Have Human Epidermal Growth Factor Recep-tor 2-Positive, Node-Negative Tumors 1 cm or Smaller. Journal of Clinical Oncology, 27, 5700-5706. [Google Scholar] [CrossRef] 
[11] Onitilo, A.A., Engel, J.M., Greenlee, R.T., et al. (2009) Breast Cancer Subtypes Based on ER/PR and Her2 Expression: Comparison of Clinicopathologic Features and Survival. Clini-cal Medicine & Research, 7, 4-13. [Google Scholar] [CrossRef] 
[12] Slamon, D.J., Clark, G.M., Wong, S.G., et al. (1987) Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/Neu Oncogene. Science, 235, 177-182. [Google Scholar] [CrossRef] [PubMed]
[13] Modi, S., Saura, C., Yamashita, T., et al. (2020) Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. The New England Journal of Medicine, 382, 610-621. [Google Scholar] [CrossRef] 
[14] Cortes, J., Kim, S.B., Chung, W.P., et al. (2022) Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. The New England Journal of Medicine, 386, 1143-1154. [Google Scholar] [CrossRef] 
[15] 雷蕾, 王晓稼. 从ADC药物发展看乳腺癌精准靶向治疗未来[J]. 肿瘤学杂志, 2021, 27(7): 515-520.
[16] Modi, S., Jacot, W., Yamashita, T., et al. (2022) Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. The New England Journal of Medicine, 387, 9-20. [Google Scholar] [CrossRef] 
[17] 王帅, 崔中豪, 杨毅. HER2阳性乳腺癌脑转移的靶向治疗研究进展[J]. 医学研究生学报, 2020, 33(2): 215-219.
[18] Brosnan, E.M. and Anders, C.K. (2018) Understanding Pat-terns of Brain Metastasis in Breast Cancer and Designing Rational Therapeutic Strategies. Annals of Translational Medi-cine, 69, Article No. 163. [Google Scholar] [CrossRef] [PubMed]
[19] Iwata, T.N., Ishii, C., Ishida, S., et al. (2018) A HER2-Targeting An-tibody-Drug Conjugate, Trastuzumab Deruxtecan (DS-8201a), Enhances Antitumor Immunity in a Mouse Model. Mo-lecular Cancer Therapeutics, 17, 1494-1503. [Google Scholar] [CrossRef] 
[20] Indini, A., Rijavec, E. and Grossi, F. (2021) Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors. International Journal of Molecular Sciences, 22, Article No. 4774. [Google Scholar] [CrossRef] [PubMed]
[21] 李佳雨, 王风华. DS-8201开启了HER2阳性晚期胃癌靶向治疗新篇章[J]. 循证医学, 2021, 21(5): 273-277.
[22] Shitara, K., Bang, Y.J., Iwasa, S., et al. (2020) Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. The New England Journal of Medicine, 382, 2419-2430. [Google Scholar] [CrossRef] 
[23] Aoki, M., Iwasa, S. and Boku, N. (2021) Trastuzumab Deruxtecan for the Treatment of HER2-Positive Advanced Gastric Cancer: A Clinical Perspective. Gastric Cancer, 24, 567-576. [Google Scholar] [CrossRef] [PubMed]
[24] Bray, F., Ferlay, J., Soerjomataram, I., et al. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424. [Google Scholar] [CrossRef] [PubMed]
[25] Díaz-Serrano, A., Gella, P., Jiménez, E., et al. (2018) Targeting EGFR in Lung Cancer: Current Standards and Developments. Drugs, 78, 893-911. [Google Scholar] [CrossRef] [PubMed]
[26] Gu, F.F., Zhang, Y., Liu, Y.Y., et al. (2016) Lung Adenocarci-noma Harboring Concomitant SPTBN1-ALK Fusion, c-Met Overexpression, and HER-2 Amplification with Inherent Resistance to Crizotinib, Chemotherapy, and Radiotherapy. Journal of Hematology & Oncology, 91, Article No. 66. [Google Scholar] [CrossRef] [PubMed]
[27] Murtuza, A., Bulbul, A., Shen, J.P., et al. (2019) Novel Third-Generation EGFR Tyrosine Kinase Inhibitors and Strategies to Overcome Therapeutic Resistance in Lung Cancer. Cancer Research, 79, 689-698. [Google Scholar] [CrossRef] 
[28] Ramalingam, S.S., Yang, J.C., Lee, C.K., et al. (2018) Osimertinib as First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 36, 841-849. [Google Scholar] [CrossRef] 
[29] Yu, H.A., Arcila, M.E., Rekhtman, N., et al. (2013) Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers. Clinical Cancer Research, 19, 2240-2247. [Google Scholar] [CrossRef] 
[30] Tsurutani, J., Iwata, H., Krop, I., et al. (2020) Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors. Cancer Discovery, 10, 688-701. [Google Scholar] [CrossRef] 
[31] Azar, I., Alkassis, S., Fukui, J., et al. (2021) Spotlight on Trastuzumab Deruxtecan (DS-8201, T-DXd) for HER2 Mutation Positive Non-Small Cell Lung Cancer. Lung Cancer (Auckland, N.Z.), 12, 103-114. [Google Scholar] [CrossRef] 
[32] Planchard, D., Yang, J.C.H., Brahmer, J.R., Ragone, A., et al. (2021) A Phase Ib Dose-Escalation Study Evaluating Trastuzumab Deruxtecan (T-DXd) and Durvalumab in Combination with Chemotherapy as First-Line Treatment in Patients with Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC) and HER2 Overexpression (DESTINY-Lung03). Journal of Thoracic Oncology, 16, S798-S798. [Google Scholar] [CrossRef] 
[33] Siena, S., Sartore-Bianchi, A., Marsoni, S., et al. (2018) Targeting the Human Epidermal Growth Factor Receptor 2 (HER2) Oncogene in Colorectal Cancer. Annals of Oncology, 29, 1108-1119. [Google Scholar] [CrossRef] [PubMed]
[34] Raghav, K., Loree, J.M., Morris, J.S., et al. (2019) Validation of HER2 Amplification as a Predictive Biomarker for Anti-Epidermal Growth Factor Receptor Antibody Therapy in Metastatic Colorectal Cancer. JCO Precision Oncology, 3, 1-13. [Google Scholar] [CrossRef] 
[35] Ross, J.S., Fakih, M., Ali, S.M., et al. (2018) Targeting HER2 in Colo-rectal Cancer: The Landscape of Amplification and Short Variant Mutations in ERBB2 and ERBB3. Cancer, 124, 1358-1373. [Google Scholar] [CrossRef] [PubMed]
[36] Sartore-Bianchi, A., Amatu, A., Porcu, L., et al. (2019) HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer. Oncologist, 24, 1395-1402. [Google Scholar] [CrossRef] [PubMed]
[37] Sawada, K., Nakamura, Y., Yamanaka, T., et al. (2018) Prognostic and Predictive Value of HER2 Amplification in Patients with Metastatic Colorectal Cancer. Clinical Colorec-tal Cancer, 17, 198-205. [Google Scholar] [CrossRef] [PubMed]
[38] Grob, T.J., Kannengiesser, I., Tsourlakis, M.C., et al. (2012) Het-erogeneity of ERBB2 Amplification in Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Undifferentiated Car-cinoma of the Lung. Modern Pathology, 25, 1566-1573. [Google Scholar] [CrossRef] [PubMed]
[39] Marx, A.H., Burandt, E.C., Choschzick, M., et al. (2010) Heterogenous High-Level HER-2 Amplification in a Small Subset of Colorectal Cancers. Human Pathology, 41, 1577-1585. [Google Scholar] [CrossRef] [PubMed]
[40] Shitara, K., Iwata, H., Takahashi, S., et al. (2019) Trastuzumab Deruxtecan (DS-8201a) in Patients with Advanced HER2-Positive Gastric Cancer: A Dose-Expansion, Phase 1 Study. The Lancet Oncology, 20, 827-836. [Google Scholar] [CrossRef] 
[41] Di Villeneuve, L., Souza, I.L., Tolentino, F.D.S., et al. (2020) Salivary Gland Carcinoma: Novel Targets to Overcome Treatment Resistance in Advanced Disease. Frontiers in Oncol-ogy, 10, Article ID: 580141. [Google Scholar] [CrossRef] [PubMed]
[42] Nam, A.R., Kim, J.W., Cha, Y., et al. (2016) Therapeutic Implica-tion of HER2 in Advanced Biliary Tract Cancer. Oncotarget, 7, 58007-58021. [Google Scholar] [CrossRef] [PubMed]
[43] English, D.P., Roque, D.M. and Santin, A.D. (2013) HER2 Ex-pression beyond Breast Cancer: Therapeutic Implications for Gynecologic Malignancies. Molecular Diagnosis & Thera-py, 17, 85-99. [Google Scholar] [CrossRef] [PubMed]
[44] Mariani, A., Sebo, T.J., Katzmann, J.A., et al. (2005) HER-2/Neu Overexpression and Hormone Dependency in Endometrial Cancer: Analysis of Cohort and Review of Literature. Anti-Cancer Research, 25, 2921-2927.
[45] Martín-Sabroso, C., Lozza, I., Torres-Suárez, A.I., et al. (2021) Anti-body-Antineoplastic Conjugates in Gynecological Malignancies: Current Status and Future Perspectives. Pharmaceutics, 13, Article No. 1705. [Google Scholar] [CrossRef] [PubMed]
[46] Tarantino, P., Modi, S., Tolaney, S.M., et al. (2021) Intersti-tial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates: A Review. JAMA Oncology, 7, 1873-1881. [Google Scholar] [CrossRef] [PubMed]
[47] Stankowicz, M., Mauro, L., Harnden, K., et al. (2021) Manage-ment of Chemotherapy-Induced Nausea and Vomiting with Trastuzumab Deruxtecan: A Case Series. Breast Care (Basel), 16, 408-411. [Google Scholar] [CrossRef] [PubMed]

为你推荐